The budget anounced on 28th evoked mixed responses from the innovator community.
Extending fiscal incentives for 5 years: Biotech,Pharma and automobile are beneficiaries. This facilities investment on long term basis.
Clinical reserach: gets a boost with service tax ecemption for testing of new drugs, including vaccines and herbal remedies as well as on human trials.
Incubators: They get recognition for the first time with service tax exemptions. See CNN video for SINE views.
VCs: Indian VCs are unhappy with passthrough benefits restricted to selected few sectors. They feel it is unwarranted as passthrough is not an incentive.
ITI: Skill set gets a boost with ITIs getting investment to update their facilities. This is probably the best news but least covered. Any reason?